Target- |
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhaseIND Approval |
First Approval Ctry. / Loc.- |
First Approval Date- |
氨磺必利注射液用于预防手术患者术后恶心呕吐的有效性和安全性的随机、双盲、与安慰剂平行对照的多中心临床试验
[Translation] A randomized, double-blind, placebo-controlled, multicenter clinical trial of the efficacy and safety of amisulpride injection for the prevention of postoperative nausea and vomiting in surgical patients
通过评价单次静脉给药后,受试者术后24h内PONV(术后恶心呕吐)的完全响应率(完全响应定义为手术结束后24h内没有呕吐发作<呕吐或干呕>,并且未使用补救治疗),证明与安慰剂相比,氨磺必利注射液预防PONV具有更好疗效。
[Translation] By evaluating the complete response rate of PONV (postoperative nausea and vomiting) within 24h of the subject after a single intravenous administration (complete response is defined as no vomiting episode within 24h after surgery, and no rescue therapy), demonstrating that amisulpride injection has better efficacy in the prevention of PONV compared with placebo.
100 Clinical Results associated with Beijing Podconley Pharmaceutical Technology Development Co., Ltd.
0 Patents (Medical) associated with Beijing Podconley Pharmaceutical Technology Development Co., Ltd.
100 Deals associated with Beijing Podconley Pharmaceutical Technology Development Co., Ltd.
100 Translational Medicine associated with Beijing Podconley Pharmaceutical Technology Development Co., Ltd.